Neumora Therapeutics, Inc. Common Stock (NMRA) NASDAQ
1.75
-0.07(-3.85%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.75
-0.07(-3.85%)
Currency In USD
| Previous Close | 1.82 |
| Open | 1.83 |
| Day High | 1.83 |
| Day Low | 1.73 |
| 52-Week High | 3.65 |
| 52-Week Low | 0.72 |
| Volume | 837,648 |
| Average Volume | 1.25M |
| Market Cap | 324.25M |
| PE | -1.32 |
| EPS | -1.33 |
| Moving Average 50 Days | 2.09 |
| Moving Average 200 Days | 2.2 |
| Change | -0.07 |
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range o
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
GlobeNewswire Inc.
Jan 05, 2026 11:35 AM GMT
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
GlobeNewswire Inc.
Jan 05, 2026 11:30 AM GMT
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety NMRA-511 demo